News briefs: Dr Reddy's launches generic Accutane; Cyprus drug shortages
Indian drugmaker Dr Reddy’s Laboratories (NYSE: RDY) says it launched Zenatane (isotretinoin capsules USP) in 20mg and 40mg, a therapeutically equivalent generic version of Swiss drug major Roche’s now off patent severe acne drug Accutane in the US market on March 28, 2013, following the approval by the US Food & Drug Administration of Dr Reddy’s ANDA.
The total market had US sales of around $309 million for the most recent 12 months ending January 2013 according to IMS Health quoted by the firm.
KEFEA says “we will not let patients go without medication”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze